CDCM 6th Annual Symposium
Save the Date: 3/24/2022
COVID alert: given the uncertainty of hosting an in-person event, we are only offering a fully virtual option for symposia participation.
Join us for the CDCM's 6th annual symposium and learn about new cell, gene, and regenerative medicine discoveries, pre-clinical development and clinical trials of curative medicines, and challenges with bringing these cures to patients to meet unmet medical needs. Exploration and discussion of these topics will be held at this one-day conference for clinicians, basic scientists, patient advocates, translational investigators, and biotech and pharmaceutical experts.
|8:30-8:35 AM||Open Zoom Waiting room|
Lloyd Minor, MD, Dean, School of Medicine, Stanford University
David Entwistle, President and CEO, Stanford Health Care
Paul King, President and CEO, Stanford Children's Health
Maria Grazia Roncarolo, MD, Director, CDCM, Stanford University
Introduction of Keynote: Maria Grazia Roncarolo
Keynote: Marina Cavazzana, MD, Director of Biotherapy Department - Hôpital Necker Enfants Malades - Paris - France
"Gene Therapy for Inherited Disease of the Hemapoietic System Between Safety and Efficacy"
Session 1 Highlights of Stem and Gene Therapy at Stanford
Moderator: Tony Oro
Lay Teng Ang, PhD, Siebel Investigator, Institute for Stem Cell Biology & Regenerative Medicine
"A Stem Cell-Based Toolkit to Study Deadly Biosafety Level 4 Viruses"
Sriram Vaidyanathan, PhD, Instructor, Department of Pediatrics, Stanford University
"Development of an Autologous Genome Edited Airway Stem Cell Therapy for Cystic Fibrosis Sinus Disease"
Session 2 Product Development and Regulatory Framework
Moderator: Steve Feldman
Isabelle Rivière, PhD, Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
Neehar Bhatia Memorial Lecture - "CAR T Cell Manufacturing in the Academic Setting"
David DiGiusto, PhD, Chief Technology Officer, Cell and Gene Therapy, National Resilience, Inc and Founding Director, Stanford Laboratory for Cell and Gene Medicine
"Challenges and Successes of Process Development and Manufacturing in Cell and Gene Therapy"
Jessica Chery, PhD, CMC Reviewer, Gene and Cell Therapy Branch, FDA
"Considerations for Development of Gene and Cell Therapy Products"
Lunch Break: "Q&A with the CDCM Experts" (individual Zoom sessions)
Mrinmoy Nag, PhD: Director of Quality Control, Laboratory for Cell and Gene Medicine, Stanford University – Quality in the GMP Setting
Sunita Rajdev, PhD: Senior Associate Director, Strategic Alliances, Office of Technology Licensing, Stanford University – Technology Licensing (will be joined by patent attorney Joe C. Hao, PhD, Kilpatrick Townsend & Stockton LLP)
Ali Bouge, MS, RAC: Director, Regulatory Affairs and Quality Assurance, Stem Cell and Gene Therapy Clinical Trials Program, Stanford University – Regulatory Management of Clinical Trials
Chaitan Khosla, PhD: Professor of Chemistry, and Director, Innovative Medicines Accelerator, Stanford University – Advancing Discoveries
Session 3 Clinical Applications and Impact on Patients
Moderator: Fraser Wright
Glenn Pierce, MD, PHD, Vice President, Medical, World Federation of Hemophilia
"Scientific, Medical, and Patient Perceptions of AAV Gene Therapies"
Crystal Mackall, MD, Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine; Founding Director, Stanford Center for Cancer Cell Therapy
"CAR T Cells for Diffuse Midline Gliomas"
Ravi Majeti MD, PhD, Professory of Medicine; Chief, Division of Hematology, Stanford University
"Reprogramming B-ALL into Antigen Presenting Cells for Cancer Vaccination"
Introduction of Keynote: Matthew Porteus, MD, PhD, Co-Director, CDCM, Stanford University
Keynote: Irv Weissman, MD, Director, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University
"Translating Stem Cell Biology into Regenerative Medicine: More Barriers Than Accelerators"
|3:00 PM||Closing Remarks: Maria Grazia Roncarolo, MD, Director, CDCM, Stanford University|